• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 3:16:03 PM ET
    $LOAC
    Business Services
    Finance
    Get the next $LOAC alert in real time by email
    SC 13G/A 1 tm216921-1_sc13ga.htm SC 13G/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    (Amendment No. 1)*

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO §240.13d-2

     

    Longevity Acquisition Corporation
    (Name of Issuer)

     

    Ordinary Shares, no par value
    (Title of Class of Securities)

     

    G56372132
    (CUSIP Number)

     

    December 31. 2020
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1 (b)

     

      x Rule 13d-1 (c)

     

      ¨ Rule 13d-1 (d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. G56372132 13G Page 2 of 6 Pages

     



    1

    NAME OF REPORTING PERSON
    Nemean Asset Management, LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    Florida

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    212,479

     

    6

    SHARED VOTING POWER
    -0-

     

    7

    SOLE DISPOSITIVE POWER
    212,479

     

    8

    SHARED DISPOSITIVE POWER
    -0-

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    212,479

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    8.1%

     

    12

    TYPE OF REPORTING PERSON*
    CO

     

           

     

     

     

     

    CUSIP No. G56372132 13G Page 3 of 6 Pages

     



    1

    NAME OF REPORTING PERSON
    Steven M. Oliveira

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S.A.

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    212,479

     

    6

    SHARED VOTING POWER
    -0-

     

    7

    SOLE DISPOSITIVE POWER
    212,479

     

    8

    SHARED DISPOSITIVE POWER
    -0-

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    212,479

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    8.1%

     

    12

    TYPE OF REPORTING PERSON*
    IN

     

           

     

     

     

     

    CUSIP No. G56372132 13G Page 4 of 6 Pages

     

    Item 1.

     

      (a) Name of Issuer: Longevity Acquisition Corporation, a British Virgin Islands company (the "Company").

     

      (b) Address of Issuer's Principal Executive Offices:

     

    The Company's principal executive offices are located at Yongda International Tower No. 2277, Longyang Road, Pudong District, Shanghai, People’s Republic of China.

     

    Item 2.

     

      (a) Name of Person Filing: Nemean Asset Management, LLC
          Steven Oliveira

     

      (b) Address of Principal Business Office or if none, Residence:

     

    Nemean Asset Management, LLC:

    225 Via Palacio

    Palm Beach Gardens, FL 33418

     

    Steven Oliveira:

    c/o Nemean Asset Management, LLC

    225 Via Palacio

    Palm Beach Gardens, FL 33418

     

      (c) Citizenship: Nemean Asset Management, LLC – Florida

    Steven Oliveira – U.S.A.

     

      (d) Title of Class of Securities:  Ordinary Shares, no par value

     

      (e) CUSIP Number:  G56372132

     

    Item 3.Not Applicable

     

    Item 4.Ownership.

     

      (a) Amount Beneficially Owned:

     

    Nemean Asset Management, LLC – 212,479 shares.

     

    Steven Oliveira – 212,479 shares.

     

    Steven Oliveira has voting and dispositive power over the securities owned by Nemean Asset Management, LLC.

     

      (b) Percent of Class:

     

    Nemean Asset Management, LLC – 8.1%

     

    Steven Oliveira – 8.1%

     

    The foregoing percentages are based on 2,626,822 Ordinary Shares outstanding as of October 7, 2020 as disclosed in the Issuer’s Form 10-Q filed with the SEC on October 7, 2020.

     

     

     

     

    CUSIP No. G56372132 13G Page 5 of 6 Pages

     

      (c) Number of shares as to which such person has:

     

      (i) sole power to vote or to direct the vote:

     

    Nemean Asset Management, LLC – 212,479 shares.

     

    Steven Oliveira – 212,479 shares.

     

      (ii) shared power to vote or to direct the vote:

     

    Nemean Asset Management, LLC – 0.

     

    Steven Oliveira – 0.

     

      (iii) sole power to dispose or to direct the disposition of:

     

    Nemean Asset Management, LLC – 212,479 shares.

     

    Steven Oliveira – 212,479 shares.

     

      (iv) shared power to dispose or to direct the disposition of:

     

    Nemean Asset Management, LLC – 0 share.

     

    Steven Oliveira – 0 share.

     

    Item 5.Ownership of Five Percent or Less of a Class: Not Applicable

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person: Not Applicable

     

    Item 7.Identification and Classification of Subsidiary Which Acquired the Securities: Not Applicable

     

    Item 8.Identification and Classification of Members of the Group: Not Applicable

     

    Item 9.Notice of Dissolution of Group: Not Applicable

     

    Item 10.Certifications: Not Applicable

     

     

     

     

    CUSIP No. G56372132 13G Page 6 of 6 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 16, 2021

     

      NEMEAN ASSET MANAGEMENT, LLC
       
      By:  /s/ Steven Oliveira
        Name: Steven Oliveira
    Title: Authorized Signatory

     

       
         /s/ Steven Oliveira
        Steven Oliveira
     

     

     

     

     

    Get the next $LOAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LOAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LOAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    4D pharma Announces Completion of Merger With Longevity Acquisition Corporation

    LEEDS, England--(BUSINESS WIRE)--4D pharma plc (Nasdaq: LBPS; AIM: DDDD) ("4D pharma" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome - today announced completion of its merger (“the Merger”) with Longevity Acquisition Corporation ("Longevity")(Nasdaq: LOAC). 4D pharma American Depositary Shares (“ADSs”) are expected to begin trading today on the Nasdaq Global Market under the ticker symbol ‘LBPS.’ Warrants of Longevity assumed by 4D pharma in the Merger are currently expected to begin trading on Nasdaq under the ticker symbol ‘LBPSW’ tomorrow, Tuesday, March 23, 2021. Lo

    3/22/21 3:00:00 AM ET
    $LOAC
    Business Services
    Finance

    Longevity Acquisition Corporation Announces Results of Special Meeting of Shareholders

    NEW YORK, March 18, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today the results of its special meeting of shareholders, which was held on March 17, 2021. At the special meeting, shareholders of the Company approved the merger, including a certain agreement and plan of merger, dated as of October 21, 2020, by and among 4d pharma plc, the Company and Dolphin Merger Sub Limited, and the related agreements and transactions contemplated thereby. About LOAC LOAC is a blank check company, also commonly referred to as a Special Purpose Acquisition Company, or SPAC, formed for the purpose of

    3/18/21 8:00:00 AM ET
    $LOAC
    Business Services
    Finance

    4D Pharma to Present at Upcoming Investor Conferences in March

    LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that 4D management will present at three upcoming investor conferences: Chardan's Virtual 3rd Annual Microbiome Medicines Summit: Monday March 8, 2021 at 11:45 am ET (16:45 GMT). H.C. Wainwright Global Life Sciences Conference: Available on-demand starting Tuesday, March 9, 2021 at 7:00 am ET (12:00 GMT). Oppenheimer’s 31st Annual Healthcare Conference: Tuesday, March 16, 2021 at 8:40 am ET (12:40 GMT). About 4D pharma Founded in February 2014, 4D pharma is a w

    3/3/21 7:00:00 AM ET
    $LOAC
    Business Services
    Finance

    $LOAC
    SEC Filings

    View All

    SEC Form EFFECT filed by Longevity Acquisition Corporation

    EFFECT - Longevity Acquisition Corp (0001743858) (Filer)

    4/7/21 12:15:42 AM ET
    $LOAC
    Business Services
    Finance

    SEC Form 15-15D filed by Longevity Acquisition Corporation

    15-15D - Longevity Acquisition Corp (0001743858) (Filer)

    4/1/21 1:05:04 PM ET
    $LOAC
    Business Services
    Finance

    SEC Form POS AM filed by Longevity Acquisition Corporation

    POS AM - Longevity Acquisition Corp (0001743858) (Filer)

    3/31/21 1:21:13 PM ET
    $LOAC
    Business Services
    Finance

    $LOAC
    Leadership Updates

    Live Leadership Updates

    View All

    4D Pharma Appoints John Beck as Chief Financial Officer and Member of the Management Team

    LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Company’s management team, bringing over 30 years of experience in finance, including three previous positions as Chief Financial Officer of publicly traded life sciences companies. “John will be an important addition to 4D pharma’s management team at such a pivotal time, as the company prepares to close our SPAC merger and begin trading on NASDAQ. His deep experience and financial expert

    3/1/21 7:00:00 AM ET
    $LOAC
    Business Services
    Finance

    $LOAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - Longevity Acquisition Corp (0001743858) (Subject)

    2/16/21 3:16:03 PM ET
    $LOAC
    Business Services
    Finance

    SEC Form SC 13G/A filed

    SC 13G/A - Longevity Acquisition Corp (0001743858) (Subject)

    2/16/21 7:36:20 AM ET
    $LOAC
    Business Services
    Finance

    SEC Form SC 13G/A filed

    SC 13G/A - Longevity Acquisition Corp (0001743858) (Subject)

    2/12/21 4:21:17 PM ET
    $LOAC
    Business Services
    Finance